UANSTEMIRanolazineIV to PO Placebo Matched IVPO RANDOMIZE (1:1)Double-blindFollow-upQ4 mo (Avg 8-12 mo)Holter at enrollment x 7dFollow-up Visits: Day 14 Month 4Q4 MonthsPrimary Endpoint: CV de